Plus Therapeutics (Nasdaq: PSTV) (@plustxinc) / X

Plus Therapeutics (Nasdaq: PSTV)

862 posts

Plus Therapeutics (Nasdaq: PSTV)

@plustxinc

Developing targeted radiotherapeutics (REYOBIQ™) and diagnostics (CNSide®) for central nervous system and brain cancers. $PSTV

Houston, TX

Joined May 2019

Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Aug 17, 2022
$PSTV Awarded $17.6M from State of #Texas Funding from #CPRIT, 2nd largest global public funder of cancer research, will support majority of development costs of 186RNL radiotherapeutic for leptomeningeal metastases bit.ly/CPRITAWARD #Metastatic #BreastCancer #LungCancer
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Mar 28, 2023
Plus Therapeutics Successfully Treats 1st Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial PR: bit.ly/3ZrWArs Website: ReSPECT-Trials.com #braincancer #btsm #glioblastoma #clinicaltrial #neurosurgery #nuclearmedicine #oncology #raredisease #radiotherapy $PSTV
00:00
7.6K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Oct 7, 2022
Live patient-focused webinar hosted by Musella Foundation this Sunday, October 9 at 6 pm CT in recognition of Breast Cancer Awareness Month. Webinar link: virtualtrials.org/webinar/ Press release: ir.plustherapeutics.com/news-releases/… #Metastatic #BreastCancer #LungCancer #ClinicalTrial $PSTV
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Mar 22, 2023
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases Press release: ir.plustherapeutics.com/news-releases/… Website: respect-trials.com/lm #bcsm #lcsm #metastatic #breastcancer #lungcancer #melanoma #radiotherapy #clinicaltrials $PSTV
00:00
6.1K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Apr 10, 2024
#ICYMI : "Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst...Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target." BusinessInsider.com article: bit.ly/3U5ePn7 $PSTV
3.3K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Sep 25, 2025
$PSTV signed a national agreement with @UHC, covering over 51 million people throughout the US, to provide the #CNSide® Cerebrospinal Fluid Tumor Cell Enumeration LDT. Read more: bit.ly/46UOXkf About CNSide®: cnside-dx.com Plus Therapeutics (Nasdaq: PSTV) IR
18K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Oct 8, 2025
Analyst Price Forecast Suggests 1,132.22% Upside: Ascendiant Capital Markets, LLC maintains its $PSTV buy recommendation. Read more:
Ascendiant Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation
From nasdaq.com
7.5K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Oct 21, 2025
$PSTV announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, @CNSideDx's Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Read more: bit.ly/42NSCya More on #CNSide:
12K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Oct 2, 2025
#PlusTherapeutics' President and CEO, Marc Hedrick, M.D., traveled to the @NasdaqExchange to speak with @RemyBlaireNews of @FINTECHTVglobal to discuss @UHC's National Coverage Agreement of @CNSideDx's Cerebrospinal Fluid Assay for #leptomeningealmetastases. Check out the
00:00
11K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Mar 20, 2023
ReSPECT-GBM Phase 1/2 clinical trial discussed in latest @theABTA e-newsletter. "A Targeted Solution in Glioblastoma Treatment" abta.org/mm-targeted-so… Learn more: ReSPECT-Trials.com #braincancer #clinicaltrials #radiotherapy $PSTV
8.1K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Nov 17, 2025
$PSTV announces it has received an additional 180-day extension period from the @Nasdaq Listing Qualifications Department to regain compliance with the $1.00 minimum bid price requirement set forth in #Nasdaq Listing Rule 5550(a)(2). No near-term reverse stock split is required
6.6K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Sep 30, 2025
$PSTV is proud to now be able to cover @CNSideDx's #CNSide® CSF Tumor Cell Enumeration laboratory developed tests through our agreement with @UHC, covering over 51 million people throughout the U.S. More on this agreement: bit.ly/46UOXkf #PSTV
CNSide Diagnostics
@CNSideDx
Sep 30, 2025
@CNSideDx's President & GM, Russell Bradley, was recently interviewed by @InnoMapHou to discuss our CNSide CSF Assay Read more: hubs.la/Q03Lqn8S0 Join our interest list: hubs.la/Q03Lqvh-0 #Oncology #Diagnostics #LMD $PSTV
ir.plustherapeutics.com
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for...
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has...
4.9K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Nov 3, 2025
Each year, #leptomeningealmetastases affects around 110,000 people in the US, yet current treatments are limited and costly. $PSTV is addressing this urgent unmet need through two key innovations: - Reyobiq™ (rhenium [Re186] obisbemeda) is #PSTV’s targeted #radiotherapeutic
ajmc.com
Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer? | AJMC
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
3.7K
Plus Therapeutics (Nasdaq: PSTV)
@plustxinc
Aug 18, 2025
#PlusTherapeutics announces positive data from the ReSPECT-LM Phase 1 single dose escalation #clinicaltrial presented at the podium at the @NeuroOnc / @ASCO #CNS Metastases Conference in Baltimore, MD. The data demonstrated treatment of #leptomeningealmetastases (LM) with
4K